Alveo Technologies just moved. Here's exactly what to do next.
Who to reach, what to say, and why now — on Alveo Technologies, plus every contract, funding round, and exec hire that follows. Verified, ICP-ranked contacts on demand (email + mobile).
Used by professionals at BlackRock, Oracle, Kleiner Perkins, HubSpot, and other leading firms — built on 10 years of proprietary signal data.
Alveo Technologies Receives Agreement from CDC to Develop Point of Need Test for Avian Influenza A(H5) Virus
Contract Type
agreement
AlamedaBiotechnologyHealth CareDescription
Alveo Technologies, Inc. has entered into an agreement with the United States Centers for Disease Control and Prevention (CDC) to develop a rapid, molecular, point of need diagnostic to detect and differentiate between Influenza A + B, and A/H5 in humans. The purpose of this agreement is to support public health preparedness by leveraging Alveo's point of need molecular testing platform for early detection of H5 and seasonal influenza viruses.